To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulations
Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden; Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
Show others and affiliations
2026 (English)In: JHEP Reports, E-ISSN 2589-5559, Vol. 8, no 3, article id 101719Article in journal (Refereed) Published
Abstract [en]

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with heterogeneous phenotypes and progression. Autoimmune traits, such as the presence of autoantibodies, are suspected to drive its heterogeneity.

METHODS: We performed a proteome-scale autoantibody screen of IgG and IgA isotypes using >42,100 protein fragments. This was followed by a validation of 1,153 selected autoantibodies, in serum samples from 466 patients with PSC in a longitudinal setting using the SUPRIM cohort and 214 controls.

RESULTS: We identified autoantibodies associated with clinical phenotypes, biochemical and clinical severity, comorbidities, and disease progression (e.g. alkaline phosphatase and albumin level p <e-10, presence of hepatobiliary malignancies p <0.001, seroconversion before transplantation p <0.001). Rather than a single universal autoantibody marker, small patient subgroups were positive for various autoantibodies with variable specificity. Global analysis of autoantigen targets revealed an overrepresentation of proteins normally expressed in immune-privileged sites, including the brain, testis, and retina. When interrogating tissue-specific autoantigen co-expression linked to expression and splicing quantitative trait loci of PSC risk variants, the thyroid emerged as an additional relevant tissue. We also detected increased autoantibody diversity associated with PSC duration and end-stage disease, already observable several years before liver transplantation. Multiomics analysis across body compartments confirmed neuroendocrine dysregulation in PSC. Our results are provided as a resource for further studies.

CONCLUSIONS: Overall, our data support the cryptic antigen and epitope-drifting autoimmune theories and indicate that neuroendocrine dysregulation may contribute to PSC pathogenesis. I

MPACT AND IMPLICATIONS: From a proteome-scale profiling of the SUPRIM cohort, we provide a short list of autoantibodies associated with clinical phenotypes and progression, along with the peptide sequences used to capture them. We identify across multiple datasets neuroendocrine deregulations in primary sclerosing cholangitis and provide a short list of related key plasma proteins. These data and technical details should facilitate validation studies, investigations of related pathophysiological mechanisms and development of low-cost tools for diagnostic or prognostic purposes.

Place, publisher, year, edition, pages
Elsevier, 2026. Vol. 8, no 3, article id 101719
Keywords [en]
SUPRIM cohort, autoantibody, cryptic antigen, epitope drifting, liver transplantation, neuro-endocrine, primary sclerosing cholangitis
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-127525DOI: 10.1016/j.jhepr.2025.101719ISI: 001694120500001PubMedID: 41732172OAI: oai:DiVA.org:oru-127525DiVA, id: diva2:2041291
Funder
Swedish Research Council, 2020-06250Swedish Research Council, 2022-01255Region Stockholm, RS2020-0731Swedish Cancer Society, 23 2665 Pj 01 H
Note

Funding Agencies:

This project received funding from the Swedish Research Council (2020-06250 to MC and 2022-01255 to AB), CIMED (FoUI-962671 to MC and FoUI-973336 to AB), RegionStockholm (RS2020-0731 to AB) and The Swedish Cancer Society (23 2665 Pj 01 H to AB).

Available from: 2026-02-24 Created: 2026-02-24 Last updated: 2026-03-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Halfvarson, Jonas

Search in DiVA

By author/editor
Halfvarson, Jonas
By organisation
School of Medical Sciences
In the same journal
JHEP Reports
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 8 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf